Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma

The present study aimed to study the efficacy and adverse effects of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T (CAR-T) cell therapy in relapsed or refractory multiple myeloma. Patients were divided into three dose groups based on cell therapy concentration. After CAR-T cell t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaohui, Ouyang, Chenxi, Sun, Guofeng, Liu, Hongfeng, Qi, Junyuan, Suo, Xiaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468803/
https://www.ncbi.nlm.nih.gov/pubmed/37664681
http://dx.doi.org/10.3892/etm.2023.12170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468803/
https://www.ncbi.nlm.nih.gov/pubmed/37664681
http://dx.doi.org/10.3892/etm.2023.12170

Ejemplares similares